A survey of Australia’s working-age population has revealed that most can’t name the most common cause of blindness among their age group – diabetic retinopathy (DR).
Read More
Aged care policies proving a major barrier for patients
Blanket policies in aged-care facilities, including complete lockdowns and two-week quarantines for residents who seek external medical treatment, have been a major barrier for patients seeking anti-VEGF treatments, the Macular Disease Foundation Australia (MDFA) has revealed.
Read More
Tackling treatment adherence in AMD
As part of Macula Month this May, Insight explores why treatment adherence remains such a major challenge for some patients and how the sector is working to overcome it.
Read More
Read More
Novartis secures approval for AMD drug in Australia
Australia’s ophthalmic community has welcomed the approval of Novartis’ latest therapy for neovascular age-related macular degeneration (nAMD). Advocates hope the decision will lift treatment adherence rates across the country.
Read More
Read More